Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

European journal of endocrinology - 1 Oct 2010

Barollo Susi, Pennelli Gianmaria, Vianello Federica, Watutantrige Fernando Sara, Negro Isabella, Merante Boschin Isabella, Pelizzo Maria Rosa, Rugge Massimo, Mantero Franco, Nacamulli Davide, Girelli Maria Elisa, Busnardo Benedetto, Mian Caterina

Abstract excerpt

OBJECTIVE: BRAF V600E is a potential marker of poor prognosis in papillary thyroid cancers (PTC). In a previous report, we showed that recurrent PTC with no radioiodine ((131)I) uptake are frequently associated with BRAF mutations, a low expression of thyroid-related genes and a high expression o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorodeoxyglucose F18

Share to Iodine Radioisotopes

Share to Kaplan-Meier Estimate

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Share to Young Adult

Source

Identifiers

PMID: 20647301
DOI: 10.1530/EJE-10-0290

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20647301-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.PMID 20647301Read ↗

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.Semantic proximity Read ↗

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity Read ↗

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerSemantic proximity Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.Semantic proximity Read ↗

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaSemantic proximity Read ↗

BRAFV600E Mutation Associated With Non–Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid CarcinomaSemantic proximity Read ↗

The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.Semantic proximity Read ↗

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.Semantic proximity Read ↗

Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid CancerSemantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.Semantic proximity Read ↗

THE RELATIONSHIP OF BRAFV600E MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.